FDA/Hill meeting on epileptic drugs
Executive Summary
Rep. Henry Waxman (D-Calif.) and Rep. Tony Coelho (D-Calif.) met with FDA Commissioner Young and Office of Drug Standards Director Peter Rheinstein, MD, on Sept. 30 to discuss concerns over the safety of epileptic drugs. Reportedly, the congressmen emphasized the need for agency caution in regulating epilepsy products. The meeting follows closely on the heels of recent anti-epilepsy drug recalls, including a Class II recall of 50 mil. carbamazepine tablets manufactured by Pharmaceutical Basics Inc.
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: